Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039052 · ClinicalTrials.gov registry record · Phase 1
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer
A Phase 1 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00039052: Completed Phase 1 study, sponsored by Neurocrine Biosciences.
NCT00039052 is a Phase 1 study that has completed, run by Neurocrine Biosciences. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00039052, a Phase 1 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances directly to solid tumor cells. PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL cytotoxin in treating patients who have recurrent or metastatic kidney cancer, non-small cell lung cancer, or breast cancer that has not responded to previous treatment.
Interventions
- BIOLOGICAL interleukin-4 PE38KDEL cytotoxin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
What the finished NCT00039052 record still lists
NCT00039052 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which interleukin-4 PE38KDEL cytotoxin is the first listed.
NCT00039052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00039052 about?
NCT00039052 is a clinical study titled "Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer". RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances directly to solid tumor cells. PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL cytotoxin in treating patients who have recurrent or metastatic kidney cancer, non-smal...
What is the current status of trial NCT00039052?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00039052?
The interventions under investigation include: interleukin-4 PE38KDEL cytotoxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00039052?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia